|
|
|
ADMS - Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing drugs for the treatment of neurological disorders. The company's lead product is GOCOVRI, an extended-release oral medication used to treat dyskinesia, a side effect of levodopa therapy commonly used to manage Parkinson's disease. Dyskinesia is characterized by abnormal involuntary movements that can significantly impact patients' quality of life.
GOCOVRI is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in Parkinson's disease patients receiving levodopa-based therapy. The drug is designed to provide a consistent release of the active ingredient, amantadine, throughout the day, which can help patients manage their dyskinesia symptoms more effectively.
In addition to GOCOVRI, Adamas Pharmaceuticals is developing other drug candidates for the treatment of neurological disorders, including a drug for the treatment of multiple sclerosis-related walking impairment and a drug for the treatment of Alzheimer's disease.
The company is committed to advancing the science and treatment of neurological disorders. Adamas Pharmaceuticals has a strong research and development team that works closely with leading academic institutions and other pharmaceutical companies to develop new treatments and expand its product pipeline.
As of September 2021, Adamas Pharmaceuticals, Inc. had a market capitalization of approximately $125 million. The company is headquartered in Emeryville, California, and operates with a small team of employees. Adamas Pharmaceuticals has partnerships with other pharmaceutical companies, including Otsuka Pharmaceutical Co., Ltd., to advance its drug development and commercialization efforts.
|
|
|
|
|
